152 related articles for article (PubMed ID: 35753082)
1. Computed DWI MRI Results in Superior Capability for N-Stage Assessment of Non-Small Cell Lung Cancer Than That of Actual DWI, STIR Imaging, and FDG-PET/CT.
Ohno Y; Yui M; Takenaka D; Yoshikawa T; Koyama H; Kassai Y; Yamamoto K; Oshima Y; Hamabuchi N; Hanamatsu S; Obama Y; Ueda T; Ikeda H; Hattori H; Murayama K; Toyama H
J Magn Reson Imaging; 2023 Jan; 57(1):259-272. PubMed ID: 35753082
[TBL] [Abstract][Full Text] [Related]
2. Diffusion-weighted MR imaging using FASE sequence for 3T MR system: Preliminary comparison of capability for N-stage assessment by means of diffusion-weighted MR imaging using EPI sequence, STIR FASE imaging and FDG PET/CT for non-small cell lung cancer patients.
Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Kassai Y; Yui M; Matsumoto S; Sugimura K
Eur J Radiol; 2015 Nov; 84(11):2321-31. PubMed ID: 26231045
[TBL] [Abstract][Full Text] [Related]
3. N stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT.
Ohno Y; Koyama H; Yoshikawa T; Nishio M; Aoyama N; Onishi Y; Takenaka D; Matsumoto S; Maniwa Y; Nishio W; Nishimura Y; Itoh T; Sugimura K
Radiology; 2011 Nov; 261(2):605-15. PubMed ID: 21926377
[TBL] [Abstract][Full Text] [Related]
4. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.
Sommer G; Wiese M; Winter L; Lenz C; Klarhöfer M; Forrer F; Lardinois D; Bremerich J
Eur Radiol; 2012 Dec; 22(12):2859-67. PubMed ID: 22772365
[TBL] [Abstract][Full Text] [Related]
5. Chemical Exchange Saturation Transfer MRI: Capability for Predicting Therapeutic Effect of Chemoradiotherapy on Non-Small Cell Lung Cancer Patients.
Ohno Y; Yui M; Yamamoto K; Takenaka D; Koyama H; Nagata H; Ueda T; Ikeda H; Ozawa Y; Toyama H; Yoshikawa T
J Magn Reson Imaging; 2023 Jul; 58(1):174-186. PubMed ID: 36971493
[TBL] [Abstract][Full Text] [Related]
6. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients.
Ohno Y; Koyama H; Nogami M; Takenaka D; Yoshikawa T; Yoshimura M; Ohbayashi C; Sugimura K
J Magn Reson Imaging; 2007 Oct; 26(4):1071-80. PubMed ID: 17896365
[TBL] [Abstract][Full Text] [Related]
7. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K
AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481
[TBL] [Abstract][Full Text] [Related]
8. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in lymph node metastases of non-small cell lung cancer (NSCLC) patients using hybrid 18F-FDG PET/MRI.
Schaarschmidt BM; Buchbender C; Nensa F; Grueneisen J; Gomez B; Köhler J; Reis H; Ruhlmann V; Umutlu L; Heusch P
PLoS One; 2015; 10(1):e0116277. PubMed ID: 25574968
[TBL] [Abstract][Full Text] [Related]
9. Editorial for "Computed DWI Results in Superior Capability for N-Stage Assessment of Non-Small Cell Lung Cancer than that of Actual DWI, STIR Imaging and FDG-PET/CT".
Laue HOA; Persigehl T
J Magn Reson Imaging; 2023 Jan; 57(1):273-274. PubMed ID: 35731616
[No Abstract] [Full Text] [Related]
10. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
[TBL] [Abstract][Full Text] [Related]
11. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy.
Takenaka D; Ohno Y; Matsumoto K; Aoyama N; Onishi Y; Koyama H; Nogami M; Yoshikawa T; Matsumoto S; Sugimura K
J Magn Reson Imaging; 2009 Aug; 30(2):298-308. PubMed ID: 19629984
[TBL] [Abstract][Full Text] [Related]
12. Use of Magnetic Resonance Imaging for N-Staging in Patients with Non-Small Cell Lung Cancer. A Systematic Review.
Brea TP; Raviña AR; Villamor JMC; Gómez AG; de Alegría AM; Valdés L
Arch Bronconeumol (Engl Ed); 2019 Jan; 55(1):9-16. PubMed ID: 29803524
[TBL] [Abstract][Full Text] [Related]
13. Diffusion-weighted MR imaging in comparison to integrated [¹⁸F]-FDG PET/CT for N-staging in patients with lung cancer.
Pauls S; Schmidt SA; Juchems MS; Klass O; Luster M; Reske SN; Brambs HJ; Feuerlein S
Eur J Radiol; 2012 Jan; 81(1):178-82. PubMed ID: 20932700
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET/CT and diffusion-weighted imaging for resected lung cancer: correlation of maximum standardized uptake value and apparent diffusion coefficient value with prognostic factors.
Usuda K; Funasaki A; Sekimura A; Motono N; Matoba M; Doai M; Yamada S; Ueda Y; Uramoto H
Med Oncol; 2018 Apr; 35(5):66. PubMed ID: 29633024
[TBL] [Abstract][Full Text] [Related]
15. Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer: which is better?
Wu LM; Xu JR; Gu HY; Hua J; Chen J; Zhang W; Haacke EM; Hu J
J Surg Res; 2012 Nov; 178(1):304-14. PubMed ID: 22541065
[TBL] [Abstract][Full Text] [Related]
16. The effectiveness of 18F-FDG PET/CT combined with STIR MRI for diagnosing nodal involvement in the thorax.
Morikawa M; Demura Y; Ishizaki T; Ameshima S; Miyamori I; Sasaki M; Tsuchida T; Kimura H; Fujibayashi Y; Okazawa H
J Nucl Med; 2009 Jan; 50(1):81-7. PubMed ID: 19091887
[TBL] [Abstract][Full Text] [Related]
17. Dynamic Contrast-Enhanced Perfusion Area-Detector CT: Preliminary Comparison of Diagnostic Performance for N Stage Assessment With FDG PET/CT in Non-Small Cell Lung Cancer.
Ohno Y; Fujisawa Y; Sugihara N; Kishida Y; Seki S; Koyama H; Yoshikawa T
AJR Am J Roentgenol; 2017 Nov; 209(5):W253-W262. PubMed ID: 28929810
[TBL] [Abstract][Full Text] [Related]
18. Amide proton transfer-weighted imaging to differentiate malignant from benign pulmonary lesions: Comparison with diffusion-weighted imaging and FDG-PET/CT.
Ohno Y; Kishida Y; Seki S; Yui M; Miyazaki M; Koyama H; Yoshikawa T
J Magn Reson Imaging; 2018 Apr; 47(4):1013-1021. PubMed ID: 28799280
[TBL] [Abstract][Full Text] [Related]
19. [Density and SUV ratios from PET/CT in the detection of mediastinal lymph node metastasis in non-small cell lung cancer].
Shao T; Yu L; Li Y; Chen M
Zhongguo Fei Ai Za Zhi; 2015 Mar; 18(3):155-60. PubMed ID: 25800571
[TBL] [Abstract][Full Text] [Related]
20. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L
Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
